Cy R. Wilkins

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia

Gerald A. Soff, Yimei Miao, Gemma Bendheim et al. · Journal of Clinical Oncology · 2019 · 130 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer

Montreh Tavakkoli, Cy R. Wilkins, Jodi V. Mones et al. · Frontiers in Oncology · 2019 · 64 citations · Full text

Medicine, Hematology, Oncology +16

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19

Ziad Bakouny, Chris Labaki, Punita Grover et al. · JAMA Oncology · 2022 · 62 citations · Full text

Life Sciences, Immunology, Oncology +17

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis

Katrina M Piedra, Tim Peterson, Carlyn Tan et al. · British Journal of Haematology · 2021 · 51 citations · Full text

Medicine, Hematology, Pharmacology +16

Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience

Gerald A. Soff, Jodi V. Mones, Cy R. Wilkins et al. · Research and Practice in Thrombosis and Haemostasis · 2019 · 33 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17